Haidar AKL

Université Libanaise, Beirut, Lebanon.

Haidar AKL holds a PhD in Biomedical and Pharmaceutical sciences from the university of Brussels (ULB). He is currently a professor of immunology at the Lebanese University, where he was involved in the setting up of a research lab on covid-19 in collaboration with the Ministry of Health. Dr AKL followed various post-doc positions at well-known laboratories such as Laboratory of Molecular and Cellular Signaling (LMCS), Gasthuisberg campus, KU Leuven and Laboratory of experimental Hematology, Bordet institute, ULB. His research shed the light on the Ca2+signaling dysregulation in Adult T-cell Leukemia (ATL), Chronic Lymphocytic Leukemia (CLL) and Diffuse Large B Cell Lymphoma (DLBCL), which can be targeted in a cell death-based anti-cancer therapy.